Cargando…

A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis

Neurofilament light chain (NfL), is a neuron-specific cytoskeletal protein detected in extracellular fluid following axonal damage. Extensive research has focused on NfL quantification in CSF, establishing it as a prognostic biomarker of disability progression in Multiple Sclerosis (MS). Our study u...

Descripción completa

Detalles Bibliográficos
Autores principales: Pafiti, Anna, Krashias, George, Tzartos, John, Tzartos, Socrates, Stergiou, Christos, Gaglia, Eftychia, Smoleski, Irene, Christodoulou, Christina, Pantzaris, Marios, Lambrianides, Anastasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341477/
https://www.ncbi.nlm.nih.gov/pubmed/37445963
http://dx.doi.org/10.3390/ijms241310787
_version_ 1785072271312814080
author Pafiti, Anna
Krashias, George
Tzartos, John
Tzartos, Socrates
Stergiou, Christos
Gaglia, Eftychia
Smoleski, Irene
Christodoulou, Christina
Pantzaris, Marios
Lambrianides, Anastasia
author_facet Pafiti, Anna
Krashias, George
Tzartos, John
Tzartos, Socrates
Stergiou, Christos
Gaglia, Eftychia
Smoleski, Irene
Christodoulou, Christina
Pantzaris, Marios
Lambrianides, Anastasia
author_sort Pafiti, Anna
collection PubMed
description Neurofilament light chain (NfL), is a neuron-specific cytoskeletal protein detected in extracellular fluid following axonal damage. Extensive research has focused on NfL quantification in CSF, establishing it as a prognostic biomarker of disability progression in Multiple Sclerosis (MS). Our study used a new commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kit and Single Molecular Array (Simoa) advanced technology to assess serum NfL levels in MS patients and Healthy Controls (HC). Verifying the most accurate, cost-effective methodology will benefit its application in clinical settings. Blood samples were collected from 54 MS patients and 30 HC. Protocols accompanying the kits were followed. The ELISA thershold was set as 3 S.D. above the mean of the HC. For Simoa, the Z-score calculation created by Jens Kuhle’s group was applied (with permission). Samples exceeding the threshold or z-score ≥1.5 indicated subclinical disease activity. To our knowledge, this is the first study to find strong-positive correlation between ELISA and Simoa for the quantification of NfL in serum (r = 0.919). Despite the strong correlation, Simoa has better analytical sensitivity and can detect small changes in samples making it valuable in clinical settings. Further research is required to evaluate whether serum NfL quantification using ELISA could be utilized to predict disability progression.
format Online
Article
Text
id pubmed-10341477
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103414772023-07-14 A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis Pafiti, Anna Krashias, George Tzartos, John Tzartos, Socrates Stergiou, Christos Gaglia, Eftychia Smoleski, Irene Christodoulou, Christina Pantzaris, Marios Lambrianides, Anastasia Int J Mol Sci Article Neurofilament light chain (NfL), is a neuron-specific cytoskeletal protein detected in extracellular fluid following axonal damage. Extensive research has focused on NfL quantification in CSF, establishing it as a prognostic biomarker of disability progression in Multiple Sclerosis (MS). Our study used a new commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kit and Single Molecular Array (Simoa) advanced technology to assess serum NfL levels in MS patients and Healthy Controls (HC). Verifying the most accurate, cost-effective methodology will benefit its application in clinical settings. Blood samples were collected from 54 MS patients and 30 HC. Protocols accompanying the kits were followed. The ELISA thershold was set as 3 S.D. above the mean of the HC. For Simoa, the Z-score calculation created by Jens Kuhle’s group was applied (with permission). Samples exceeding the threshold or z-score ≥1.5 indicated subclinical disease activity. To our knowledge, this is the first study to find strong-positive correlation between ELISA and Simoa for the quantification of NfL in serum (r = 0.919). Despite the strong correlation, Simoa has better analytical sensitivity and can detect small changes in samples making it valuable in clinical settings. Further research is required to evaluate whether serum NfL quantification using ELISA could be utilized to predict disability progression. MDPI 2023-06-28 /pmc/articles/PMC10341477/ /pubmed/37445963 http://dx.doi.org/10.3390/ijms241310787 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pafiti, Anna
Krashias, George
Tzartos, John
Tzartos, Socrates
Stergiou, Christos
Gaglia, Eftychia
Smoleski, Irene
Christodoulou, Christina
Pantzaris, Marios
Lambrianides, Anastasia
A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis
title A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis
title_full A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis
title_fullStr A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis
title_full_unstemmed A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis
title_short A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis
title_sort comparison of two analytical approaches for the quantification of neurofilament light chain, a biomarker of axonal damage in multiple sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341477/
https://www.ncbi.nlm.nih.gov/pubmed/37445963
http://dx.doi.org/10.3390/ijms241310787
work_keys_str_mv AT pafitianna acomparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT krashiasgeorge acomparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT tzartosjohn acomparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT tzartossocrates acomparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT stergiouchristos acomparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT gagliaeftychia acomparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT smoleskiirene acomparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT christodoulouchristina acomparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT pantzarismarios acomparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT lambrianidesanastasia acomparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT pafitianna comparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT krashiasgeorge comparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT tzartosjohn comparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT tzartossocrates comparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT stergiouchristos comparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT gagliaeftychia comparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT smoleskiirene comparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT christodoulouchristina comparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT pantzarismarios comparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis
AT lambrianidesanastasia comparisonoftwoanalyticalapproachesforthequantificationofneurofilamentlightchainabiomarkerofaxonaldamageinmultiplesclerosis